Core Viewpoint - BioPorto A/S has announced preliminary unaudited financial figures for 2025, providing guidance for 2026 and an update on its business strategy, indicating strong growth in its NGAL product line and a focus on expanding market adoption in the U.S. [1][4][11] Financial Performance - In Q4 2025, total revenue reached DKK 11.6 million, a 47% increase compared to Q4 2024, with a 52% increase at constant exchange rates [3][8] - For the fiscal year 2025, total revenue was DKK 40.3 million, up 11% from DKK 36.2 million in 2024, with a 13% increase at constant exchange rates [3][8] - Total NGAL revenue for FY 2025 was DKK 28.2 million, reflecting a 22% growth year-over-year [3][8] - The adjusted EBITDA loss for FY 2025 is estimated at approximately DKK 77 million, aligning with previous guidance [3][8] 2026 Financial Guidance - For 2026, BioPorto targets total revenue of DKK 48-58 million, representing a growth of 20-45% [6][9] - Total NGAL revenue is expected to grow by 20-50%, reaching DKK 33-42 million [6][9] - The adjusted EBITDA loss for 2026 is projected to be between DKK 50-60 million, indicating a decrease in loss of 22-35% compared to 2025 [9] Business Strategy and Market Adoption - The company is pursuing over 60 active hospitals in the U.S. by the end of 2026 as part of its "Forward" strategy [6][11] - By the end of 2025, there were 44 active hospitals using NGAL for Research Use Only (RUO), an increase of 8 from the previous year [14] - BioPorto is preparing for a clinical validation study for adults, with a pre-submission package to the FDA expected by the end of Q1 2026 [14] Future Aspirations - The company aims for revenue between DKK 150-200 million by FY 2028, with an adjusted EBITDA margin of at least 15% [9] - Cash flow is expected to turn positive in the second half of 2027, with current cash reserves projected to cover expenses through 2026 [9]

Core Viewpoint - BioPorto A/S has announced preliminary unaudited financial figures for 2025, providing guidance for 2026 and an update on its business strategy, indicating strong growth in revenue driven by its NGAL product line, particularly in the U.S. market [1][4][6]. Financial Performance - In Q4 2025, total revenue reached DKK 11.6 million, a 47% increase compared to Q4 2024, with a 52% increase at constant exchange rates [3][7]. - For the fiscal year 2025, total revenue was DKK 40.3 million, an 11% increase from DKK 36.2 million in 2024, with a 13% growth at constant exchange rates [3][7]. - Total NGAL revenue for FY 2025 was DKK 28.2 million, reflecting a 22% increase from the previous year [3][7]. - The adjusted EBITDA loss for FY 2025 is estimated at DKK 77 million, aligning with the guidance of a loss between DKK 75-80 million [3][7]. 2026 Financial Guidance - For 2026, BioPorto expects total revenue to be between DKK 48-58 million, representing a growth of 20-45% [6][8]. - Total NGAL revenue is projected to grow by 20-50%, reaching DKK 33-42 million [6][8]. - The adjusted EBITDA loss for 2026 is anticipated to be between DKK 50-60 million, indicating a decrease in loss of 22-35% compared to 2025 [8]. Business Strategy and Market Adoption - The company is focused on executing its "Forward" strategy, aiming to increase market adoption of its NGAL test, with a target of over 60 active hospitals in the U.S. by the end of 2026 [6][10][12]. - By the end of 2025, BioPorto had established 44 active hospitals for NGAL RUO, an increase of 8 from the previous year [12]. - The company is preparing for a clinical validation study for adults, with a pre-submission package to the FDA expected by the end of Q1 2026 [12]. Future Aspirations - BioPorto aims for revenue between DKK 150-200 million by FY 2028, with an adjusted EBITDA margin of at least 15% [8]. - The company expects to achieve positive cash flow in the second half of 2027, with current cash reserves projected to cover expenses through 2026 [8].

Core Viewpoint - BioPorto A/S reported continued growth in NGAL sales and outlined strategic milestones in its "Forward" strategy aimed at transforming kidney care globally [1][5]. Financial Performance - Revenue for Q3 2025 reached DKK 10.4 million, a 7% increase year-over-year, and a 10% increase at constant exchange rates [9]. - Total revenue for the first nine months of 2025 was DKK 28.7 million, reflecting a 1% increase compared to the same period last year, with a 2% increase at constant exchange rates [9][10]. - NGAL sales in Q3 2025 totaled DKK 7.2 million, growing by 5% globally and 10% at constant exchange rates [9]. - For the first nine months of 2025, NGAL sales rose by 5% compared to the same period in 2024, and by 7% at constant exchange rates [10]. Strategic Developments - The company successfully delivered its first ProNephro AKI (NGAL) order to the US market in August 2025, marking a significant step in its commercial launch [8]. - Patient enrollment for the clinical cut-off study was completed by the end of October 2025, with a focus on thorough data analysis to ensure high-quality validation study design [4][8]. - The FDA submission has been postponed to the first half of 2027 to align with the updated study design based on FDA feedback [4][8]. Capital and Funding - On November 13, 2025, BioPorto completed a share issuance, raising approximately DKK 43 million, which is expected to support operations through 2026 [6][8]. - The company aims to achieve positive cash flow in the second half of 2027 [6]. Future Guidance - The full-year guidance for 2025 remains unchanged, with total revenue expected to be in the range of DKK 40-45 million and an Adjusted EBITDA loss projected between DKK 75-80 million [11][16].